Caplin Point Laboratories Ltd vs Concord Drugs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Caplin Point Laboratories Ltd is ₹ 1743 as of 04 May 11:00 . The P/E Ratio of Caplin Point Laboratories Ltd changed from 12.6 on March 2021 to 28.4 on March 2025 . This represents a CAGR of 17.65% over 5 yearsThe P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 91.4 on March 2025 . This represents a CAGR of 54.84% over 4 years The Market Cap of Caplin Point Laboratories Ltd changed from ₹ 3057 crore on March 2021 to ₹ 15222 crore on March 2025 . This represents a CAGR of 37.86% over 5 yearsThe Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 31.08 crore on March 2025 . This represents a CAGR of 5.22% over 4 years The revenue of Caplin Point Laboratories Ltd for the Dec '25 is ₹ 576.45 crore as compare to the Sep '25 revenue of ₹ 564.43 crore. This represent the growth of 2.13% The revenue of Concord Drugs Ltd for the Dec '25 is ₹ 16.99 crore as compare to the Sep '25 revenue of ₹ 10.28 crore. This represent the growth of 65.27% The ebitda of Caplin Point Laboratories Ltd for the Dec '25 is ₹ 223.35 crore as compare to the Sep '25 ebitda of ₹ 219.56 crore. This represent the growth of 1.73% The ebitda of Concord Drugs Ltd for the Dec '25 is ₹ 0.94 crore as compare to the Sep '25 ebitda of ₹ 1.1 crore. This represent the decline of -14.55% The net profit of Caplin Point Laboratories Ltd changed from ₹ 124.92 crore to ₹ 165.86 crore over 7 quarters. This represents a CAGR of 17.58% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.22 crore over 7 quarters. This represents a CAGR of 212.22% The Dividend Payout of Caplin Point Laboratories Ltd changed from 14.53 % on March 2021 to 13.43 % on March 2025 . This represents a CAGR of -1.56% over 5 yearsThe Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Caplin Point Laboratories Ltd

Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16, 1990.
The Company is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market.
Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India.
It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections. Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries.
In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well.

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

FAQs for the comparison of Caplin Point Laboratories Ltd and Concord Drugs Ltd

Which company has a larger market capitalization, Caplin Point Laboratories Ltd or Concord Drugs Ltd?

Market cap of Caplin Point Laboratories Ltd is 13,002 Cr while Market cap of Concord Drugs Ltd is 112 Cr

What are the key factors driving the stock performance of Caplin Point Laboratories Ltd and Concord Drugs Ltd?

The stock performance of Caplin Point Laboratories Ltd and Concord Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Caplin Point Laboratories Ltd and Concord Drugs Ltd?

As of May 4, 2026, the Caplin Point Laboratories Ltd stock price is INR ₹1710.6. On the other hand, Concord Drugs Ltd stock price is INR ₹85.13.

How do dividend payouts of Caplin Point Laboratories Ltd and Concord Drugs Ltd compare?

To compare the dividend payouts of Caplin Point Laboratories Ltd and Concord Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.